Reprint of "Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells"

被引:7
|
作者
Samper, Katia G. [1 ,2 ]
Marker, Sierra C. [1 ]
Bayon, Pau [2 ]
MacMillan, Samantha N. [1 ]
Keresztes, Ivan [1 ]
Palacios, Oscar [2 ]
Wilson, Justin J. [1 ]
机构
[1] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA
[2] Univ Autonoma Barcelona, Fac Ciencies, Dept Quim, E-08193 Barcelona, Spain
关键词
Cisplatin; Cisplatin resistance; Antitumor drug; Ovarian cancer; Azobenzene; Photodynamic therapy; PHOTOSWITCHABLE ARENE RUTHENIUM; DIMETHYLSULFOXIDE COMPLEXES; PHOTODYNAMIC THERAPY; CLINICAL-USE; PT-195; NMR; DNA; CYTOTOXICITY; LIGANDS; AGENTS; CARBOPLATIN;
D O I
10.1016/j.jinorgbio.2017.07.035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The syntheses of three platinum(II) complexes bearing sulfonamide-((E)-2-(4-methylphenylsulfonamido)-2',6'-difluoroazobenzene, HL1) and hydroxy-azo-2,6-difluorobenzene ((E)-2-((2,6-difluorophenyl)diazenyl)phenol, HL2) bidentate ligands is described. These complexes, [Pt(L1)(DMSO)Cl] (1), [Pt(L2)(DMSO)Cl] (2), and [Pt(L2)2] (3), were characterized by multinuclear NMR spectroscopy, mass spectrometry, and X-ray crystallography. Despite bearing azobenzene functional groups, none of the three complexes undergo photoisomerization. The anticancer activities of these complexes were evaluated in wild-type (A2780) and cisplatin-resistant (A2780CP70) ovarian cancer cells. All three complexes exhibited IC50 values below 10 mu M and displayed similar activity in both A2780 and A2780CP70 cell lines, indicating that they are not cross-resistant with cisplatin. The DNA-binding properties of 1-3 were investigated by circular dichroism spectroscopy and by agarose gel electrophoresis. Both studies suggest that 1 and 2 form monofunctional DNA adducts.
引用
收藏
页码:335 / 343
页数:9
相关论文
共 50 条
  • [41] Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells
    Sarkhosh-Inanlou, Roya
    Molaparast, Morteza
    Mohammadzadeh, Adel
    Shafiei-Irannejad, Vahid
    CHEMICAL BIOLOGY & DRUG DESIGN, 2020, 95 (02) : 215 - 223
  • [42] Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells
    Zhang, Haiyuan
    Wu, Jiu-Sheng
    Peng, Fangyu
    ANTI-CANCER DRUGS, 2008, 19 (02) : 125 - 132
  • [43] Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells
    Marzano, Christine
    Gandin, Valentina
    Folda, Alessandra
    Scutari, Guido
    Bindoli, Alberto
    Rigobello, Maria Pia
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 42 (06) : 872 - 881
  • [44] Cantrixil targets ovarian cancer stem cells and prevents recurrence in a cisplatin-resistant animal model
    Mor, Gil G.
    Lima, Eydis
    Sumi, Natalia
    Pitruzzello, Mary
    Yang-Hartwich, Yang
    Brown, David
    Heaton, Andrew
    Alvero, Ayesha B.
    CANCER RESEARCH, 2015, 75
  • [45] Cisplatin-Resistant Ovarian Cancer Cells Reveal a Polyploid Phenotype with Remarkable Activation of Nuclear Processes
    Adibi, Rezvan
    Moein, Shiva
    Gheisari, Yousof
    ADVANCED BIOMEDICAL RESEARCH, 2023, 12 (01):
  • [46] Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study
    Gokduman, Kurtulus
    NANOMEDICINE, 2019, 14 (24) : 3177 - 3191
  • [47] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [48] Anticancer activity of a trans-platinum(II) complex of 3-aminoflavone to ovarian cancer cells
    Orzechowska, Magdalena
    Fabijanska, Malgorzata
    Ochocki, Justyn
    Malecki, Maciej
    GINEKOLOGIA POLSKA, 2017, 88 (02) : 68 - 74
  • [49] Platinum-AIEgen coordination complex for imaging-guided annihilation of cisplatin-resistant cancer cells
    He, Zhenyan
    Gao, Yuting
    Zhang, Haoke
    Wang, Xiuxia
    Meng, Fanling
    Luo, Liang
    Tang, Ben Zhong
    CHEMICAL COMMUNICATIONS, 2020, 56 (56) : 7785 - 7788
  • [50] Expression of Ferredoxin1 in cisplatin-resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
    Takahashi, Ryosuke
    Kamizaki, Koki
    Yamanaka, Keitaro
    Terai, Yoshito
    Minami, Yasuhiro
    ONCOLOGY REPORTS, 2023, 49 (06)